What is Veracyte's indefinite- lived intangible impairment?

Veracyte (VCYT) reported indefinite- lived intangible impairment of $152.92M in Q1 2026.

How has Veracyte's indefinite- lived intangible impairment changed year-over-year?

Veracyte's indefinite- lived intangible impairment decreased by 0.0% year-over-year, from $152.92M to $152.92M.

What is the long-term trend for Veracyte's indefinite- lived intangible impairment?

Over 5 years (2020 to 2025), Veracyte's indefinite- lived intangible impairment has grown at a 16.8% compound annual growth rate (CAGR), from $70.42M to $152.92M.

Veracyte VCYT Indefinite- lived intangible impairment

Indefinite- lived intangible impairment at other companies

Bio-Rad LaboratoriesBIO

——

Labcorp HoldingsLH

——

Agilent TechnologiesA

——

Lantheus HoldingsLNTH

——

ZoetisZTS

——

Other financials

Income statement

See full

Revenue$139.1M+21.5%

Gross profit$101.2M+27.2%

Operating income$22.6M+680%

Net income$28.7M+307%

EPS (diluted)$0.35+289%

Balance sheet

See full

Cash & equivalents$264.8M+41.0%

Total debt$39.3M-22.1%

Total equity$1.3B+12.5%

Total assets$1.4B+9.2%

Cash flow

See full

Operating cash flow$35.2M+557%

CapEx$3.0M+62.8%

Free cash flow$32.3M+810%

Valuation

See full

Market cap$4.29B+10.7%

Profitability

See full

Gross margin70.9%+2.9pp

Operating margin14.3%+9.2pp

Net margin16.2%+9.1pp

FCF margin28.7%+11.7pp

Returns & leverage

See full

Return on equity6.9%+4.1pp

Debt / equity0×0.0×

Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsGrossExcludingGoodwill.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's indefinite- lived intangible impairment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Veracyte's indefinite- lived intangible impairment?: Veracyte (VCYT) reported indefinite- lived intangible impairment of $152.92M in Q1 2026.
How has Veracyte's indefinite- lived intangible impairment changed year-over-year?: Veracyte's indefinite- lived intangible impairment decreased by 0.0% year-over-year, from $152.92M to $152.92M.
What is the long-term trend for Veracyte's indefinite- lived intangible impairment?: Over 5 years (2020 to 2025), Veracyte's indefinite- lived intangible impairment has grown at a 16.8% compound annual growth rate (CAGR), from $70.42M to $152.92M.